{"organizations": [], "uuid": "32b6c2c7b794ad975fe4e046f9f75360de1a01c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-teva-announces-launch-of-offering/brief-teva-announces-launch-of-offering-of-senior-notes-idUSASB0C80R", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Announces Launch Of Offering Of Senior Notes", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T16:05:00.000+02:00", "replies_count": 0, "uuid": "32b6c2c7b794ad975fe4e046f9f75360de1a01c1"}, "author": "", "url": "https://www.reuters.com/article/brief-teva-announces-launch-of-offering/brief-teva-announces-launch-of-offering-of-senior-notes-idUSASB0C80R", "ord_in_thread": 0, "title": "BRIEF-Teva Announces Launch Of Offering Of Senior Notes", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "teva pharmaceutical industries ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd - unit", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 05 PM / in 13 minutes BRIEF-Teva Announces Launch Of Offering Of Senior Notes Reuters Staff Feb 28 (Reuters) - Teva Pharmaceutical Industries Ltd : * TEVA ANNOUNCES LAUNCH OF OFFERING OF SENIOR NOTES * TEVA PHARMACEUTICAL INDUSTRIES LTD - UNIT INTENDS TO OFFER EUR 1 BILLION AGGREGATE PRINCIPAL AMOUNT OF EUR-DENOMINATED SENIOR NOTES IN ONE OR MORE SERIES * TEVA PHARMACEUTICAL-TO USE NET PROCEEDS TO REPAY ABOUT $2.3 BILLION OUTSTANDING INDEBTEDNESS UNDER U.S. DOLLAR AND JAPANESE YEN TERM LOAN AGREEMENTS * TEVA PHARMACEUTICAL INDUSTRIES LTD - EXPECTS TO GIVE NOTICE OF ITS INTENTION TO REDEEM ALL OF ITS 1.40% SENIOR NOTES DUE 2018 * TEVA PHARMACEUTICAL - EXPECTS TO USE NET PROCEEDS WITH CASH ON HAND, TO REPAY $1.5 BILLION OUTSTANDING INDEBTEDNESS UNDER 1.40% SENIOR NOTES DUE 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-28T16:05:00.000+02:00", "crawled": "2018-02-28T16:23:26.005+02:00", "highlightTitle": ""}